Express News | Shenzhen Neptunus Bioengineering: NEP018 tablets have received approval for clinical drug trials.

BreakingsMar 10 16:25

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Neptune Biotech: 2024 Annual Results Forecast

SZSIJan 23 00:00 · Announcements

Express News | Shenzhen Neptunus Bioengineering: Expected losses in 2024 will be between 0.95 billion yuan and 1.2 billion yuan.

BreakingsJan 22 17:01

Express News | Shenzhen Neptunus Bioengineering: The medical instruments Business is less affected by centralized procurement and significant matters of the company are still in progress.

BreakingsJan 8 20:23

shenzhen neptunus bioengineering (000078.SZ): The company's current medical device business is about tens of billions in scale.

On November 13, Glonghui reported that shenzhen neptunus bioengineering (000078.SZ) stated in its investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business and is relatively less affected by policies. Therefore, the medical device business is one of the key sectors for the company's development, with the current medical device business scale at about 10 billion. In the future, the company will expand the scale of its medical device agency and direct sales business, aiming to transform from a market agent to a company with foreign brand agency rights, introducing advanced technologies and high-quality products from foreign brands to further enhance the company's medical device business level and market competitiveness.

Gelonghui FinanceNov 13, 2024 21:09